title: Expression of Rb, pRb2/p130, p53, and p16 proteins in malignant melanoma of oral mucosa.
abstract: We previously reported that pRb2/p130 gene, one of the Rb family members, was immunohistochemically abundantly expressed in well-differentiated oral squamous cell carcinomas, whereas in undifferentiated ones the expression was low. Oral malignant melanoma is extremely rare, however the prognosis is poor because it tends to locally invade tissue or metastasize and its biological behavior appears to be different from cutaneous malignant melanoma. The present study dealt with the expression of pRb2/p130, Rb, p53, and p16 in 13 cases of malignant melanoma of oral mucosa as revealed by immunohistochemical staining. The stage classification of the 13 patients was as follows; stage II: eight patients, stage III: three patients, and stage IV: two patients. pRb2/p130 was expressed in only two stage II-cases, neither of which have shown any evidence of recurrence or metastasis for over 14 years. Positive staining for Rb was found in three cases consisting of one stage II-case, one stage III-case, and one stage IV-case. p53 was expressed in two cases, one a stage II and the other a stage IV. Positive staining for p16 was found in seven cases consisting of four stage II-cases, two stage III-cases, and one stage IV-case. pRb2/p130 may be inversely correlated with the malignancy of oral malignant melanoma, but further study is needed.
authors: Department of Oral Surgery, Sapporo Medical University School of Medicine, Japan. ntanaka@sapmed.ac.jp
authors: N
authors: N
authors: Tanaka
authors: T
authors: T
authors: Odajima
authors: M
authors: M
authors: Mimura
authors: K
authors: K
authors: Ogi
authors: H
authors: H
authors: Dehari
authors: Y
authors: Y
authors: Kimijima
authors: G
authors: G
authors: Kohama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D005260:Female; D005887:Gingival Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D008048:Lip Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D009061:Mouth Mucosa / Q000737:chemistry / Q000473:pathology; D009062:Mouth Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D009363:Neoplasm Proteins / Q000032:analysis*; D009367:Neoplasm Staging; D010157:Palatal Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D010750:Phosphoproteins / Q000032:analysis; D011506:Proteins; D016160:Retinoblastoma Protein / Q000032:analysis; D050717:Retinoblastoma-Like Protein p130; D014062:Tongue Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D010750:Phosphoproteins; D011506:Proteins; C493837:RBL2 protein, human; D016160:Retinoblastoma Protein; D050717:Retinoblastoma-Like Protein p130; D016159:Tumor Suppressor Protein p53